Explore a comprehensive medical lecture where Dr. Shonali Midha from Dana-Farber Cancer Institute examines the emerging role and therapeutic potential of bispecific antibodies in treating relapsed/refractory multiple myeloma, providing valuable insights into this innovative treatment approach for healthcare professionals and researchers in the field of hematologic oncology.
Bispecific Antibody Therapy for Treating Relapsed and Refractory Multiple Myeloma
Dana-Farber Cancer Institute via YouTube
Overview
Syllabus
Bispecific Antibody Therapy in Multiple Myeloma
Taught by
Dana-Farber Cancer Institute
Related Courses
-
Bispecific Antibodies in Multiple Myeloma
-
Future of Novel Next-Generation Therapy in the Management of Relapsed/Refractory Multiple Myeloma
-
CAR T-Cell Therapy for Multiple Myeloma Treatment and New Therapeutic Approaches
-
Continued Evolution of Therapy for Patients with Newly Diagnosed Multiple Myeloma
-
Future Directions for Novel and Next Generation Therapy in Multiple Myeloma
-
The Evolution of Systemic Therapy for Newly Diagnosed Multiple Myeloma
